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INTRODUCTION
Gastroesophageal reflux disease (GERD) is characterised
by abnormal excessive acidic gastric content reflux in
esophagus and it has complex pathophysiology (Mulholland
et al., 1989; Collen and Johnson, 1992; Abe et al., 2009).
Production of gastric acid is controlled by various physio-
logical mechanisms, involving gastrin-17 (G-17) exclu-
sively produced by the G cells located in the antral mucosa
of stomach (Gritti et al., 2000; Dockray, 2004). G-17 is cru-
cial acid secretion stimulator, controlled via negative feed-
back mechanisms.
Pepsinogen-1 (Pg1), a precursor of pepsin, is produced by
the chief and mucus cells located in the corpus mucosa of
the stomach. Pepsinogen-2 (Pg2) is produced not only in the
corpus mucosa, but also in antral and duodenal mucosa
(Gritti et al., 2000). Some studies have demonstrated differ-
ent gastric acid exposure profiles among various forms of
erosive reflux disease (Mulholland et al., 1989; Collen and
Johnson, 1992). Since the levels of these biomarkers reflect
functional state of the gastric mucosa, they are used for
non-invasive diagnosis and screening for atrophic gastritis
(Kuipers, 2003; Vaananen et al., 2003; Pasechnikov et al.,
2005; Iijima et al., 2009; Narsollahzadeh et al., 2011). For
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Gastrin-17 (G-17), pepsinogen-1 (Pg1) and pepsinogen-2 (Pg2) reflect the functional state of gas-
tric mucosa and are used for non-invasive diagnosis and screening of atrophic gastritis. The aim
of the study was to clarify if erosive reflux disease (ERD) or non-ERD (NERD) can be distin-
guished from other dyspeptic conditions in patients, in a non-invasive manner using specific
biomarkers. Levels of G-17, Pg1, and Pg2 were measured in 141 ERD patients (median age 48
years, males — 68), 122 NERD patients (median age 45 years, males — 32) and 410 control pa-
tients (median age 50 years, males — 97). Levels of biomarkers in ERD and NERD groups were
compared to controls. Median levels of G-17 (1.94 vs 2.92 pmol/L, p = 0.036) and Pg2 (6.70 vs
7.79 µg/l, p = 0.046) were lower in the ERD group compared to control patients; no difference
with respect to the control was found for the NERD group. After exclusion of the patients having
at least one potential condition that might modify the levels of the biomarkers (gastric mucosa at-
rophy, Helicobacter pylori colonisation), no difference in levels of biomarkers was observed with
respect to the control for both the ERD and NERD groups. G-17, Pg1, and Pg2 based tests can-
not be used to distinguish ERD or NERD from other dyspeptic conditions in patients.
Key words: gastroesophageal reflux disease, gastrin-17, pepsinogen-1, pepsinogen-2.
172 Proc. Latvian Acad. Sci., Section B, Vol. 72 (2018), No. 3.
example, an increased level of G-17 may reflect atrophy of
corpus mucosa or inflammation of antral mucosa, while a
decreased G-17 level suggests atrophy of the antral mucosa.
All of these biomarkers are involved in the secretion and
production of the gastric acid, but it still remains unclear if
there is any association among levels of biomarkers and
gastroesophageal reflux disease.
The aim of the study was to clarify if Erosive reflux disease
(ERD) or non-ERD (NERD) could be distinguished from
other dyspeptic conditions in patients, in a non-invasive
manner using G-17, Pg1, and Pg2 based tests.
MATERIALS AND METHODS
Study design. Patients with various complaints concerning
the side of upper gastrointestinal system, who visited the
outpatient department of Rîga East Clinical University Hos-
pital (Rîga, Latvia) and Centre of Digestive Diseases “GAS-
TRO” (Rîga, Latvia) during the time period 2005–2011,
were invited to participate in the study. In total 841 dyspep-
tic patients were interviewed and asked to fill in a special
questionnaire about their complaints (heartburn, acid regur-
gitation, loss of appetite, postprandial fullness, early satia-
tion, epigastric pain, vomitus and other), medical history
(cancer anamnesis, previous operations etc.) and history of
drug usage (proton pump inhibitors, Helicobacter pylori
eradication therapy and histamine-2 antagonists).
In the questionnaire about patient complaints, the patients
answered “yes” or “no” to all questions except those about
heartburn and acid regurgitation (Table 1). Dyspepsia was
defined in accordance to the Rome III criteria as the pres-
ence of at least one of four cardinal dyspepsia symptoms
(postprandial fullness, early satiation, epigastric pain or epi-
gastric burning), in the absence of organic or metabolic dis-
turbances likely to explain those symptoms (Tack et al.,
2006). After the interview a blood sample was taken from
each patient and then upper gastrointestinal endoscopy with
standard biopsy was performed.
The following inclusion criteria were used: dyspeptic pa-
tients identified as Rome III criteria, age at least 18 years,
non-pregnant, willing to participate in the study and did not
meet exclusion criteria.
The following exclusion criteria were used: use of proton
pump inhibitors and/or histamine-2 antagonists during the
last month, active ulcer disease, gastric cancer, gastric lym-
phoma, Barrett’s esophagus (BE), hiatus hernia of eso-
phagus and history of any type of gastric surgery.
According to the medical history and endoscopic finding,
the patients (n = 673) were divided into three groups (Katz
et al., 2013): the ERD group consisted of patients with visi-
ble esophageal mucosa breaks (ulcers and/or erosions) ele-
vated according to the Los Angeles classification (Lundell
et al., 1999), NERD patients were defined as having symp-
toms with known quality and duration (heartburn and/or
acid regurgitation appearing at least twice a week for at
least six months) and having no visible esophageal mucosa
breaks (Dixon et al., 1996), and a control group was com-
posed of other patients with various complaints about the
upper gastrointestinal system’s side and having no evidence
of any form of gastroesophageal reflux disease.
Levels of detected biomarkers and their ratios in the ERD
and NERD study groups were compared to control patients.
To clarify if changes in the levels of the biomarkers were
influenced by underlying changes of gastric mucosa, the
levels of the biomarkers and their ratios were compared
among patient groups after exclusion of all patients having
at least one potential condition that might modify the levels
of the biomarkers (gastric corpus and antrum mucosa atro-
phy, Helicobacter pylori colonisation of gastric mucosa).
Plasma biomarkers. A blood sample from each patient was
taken after night fasting prior to upper gastrointestinal endo-
scopy or 24 hours after the procedure. Blood plasma was
separated from the whole blood, frozen immediately and
stored at –80 °C in the laboratory. Then, levels of Pg1, Pg2
and G-17 was measured by specific enzyme linked immu-
nosorbent assay (Pepsinogen-I EIA Test kit, Pepsinogen-II
EIA Test kit and Gastrin-17 EIA Test kit, GastroPanel®,
Biohit Oyj., Helsinki, Finland) according to the manufac-
ture’s instructions. In addition the Pg1 and Pg2 ratio
(Pg1/Pg2) was calculated.
Upper gastrointestinal tract endoscopy. Upper gastroin-
testinal tract endoscopy was done after night fasting. Pres-
ence of esophageal mucosa breaks (ulcers and/or erosions)
was evaluated according to Los Angeles classification (Lun-
dell et al., 1999). Standard biopsy material from each pa-
tient was taken during the procedure from at least five dif-
ferent loci of the stomach in accordance to the updated
Sydney system: two from corpus mucosa (one from the
lesser and one from the greater curvature), one from in-
cisura angularis mucosa (from the lesser curvature) and
two from antrum mucosa (one from the lesser and one from
the greater curvature) (Dixon et al., 1996). Additional biop-
sies were taken from any columnar-lined mucosa of the
lower part of esophagus.
Histopathology. An experienced expert gastrointestinal
histopathologist (DJ), blinded from any clinical data, exam-
ined all of the biopsies. All findings were reported sepa-
rately for each site of stomach: corpus, incisura angularis
and antrum. Staining with haematoxylin and eosin was done
for evaluation of gastric mucosa atrophy. Giemsa staining
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T a b l e 1
PATIENT COMPLAINTS
Number of patients (n = 673)
Heartburn Acid regurgitation
All the time 99 45
Every day 45 19
Twice a week 9 2
Sometimes 6 1
Never 514 606
was used to determine density of Helicobacter pylori gastric
mucosa colonisation.
The loss of appropriate glands with or without metaplastic
epithelial transformation was defined as mucosa atrophy
and was scored using visual analogue scales (0 = absent, 1 =
mild, 2 = moderate, 3 = severe) (Dixon et al., 1996).
Biopsies from the incisura angularis and antrum mucosa
were considered as the antral mucosa. The highest score for
estimated parameters was used in the analysis.
The diagnosis of Barrett’s esophagus was made if the spe-
cialised metaplastic columnar epithelium with goblet and/or
pre-goblet cells was confirmed by histopathological exami-
nation in biopsy samples taken from any columnar-lined
mucosa of the lower part of esophagus.
Statistical analysis. Distribution of age was characterised
using median and range. Frequency of gender is shown in
per cents. Distribution of biomarkers and their ratio was
characterised by median and interquartile range (IQR =
Q1–Q3). Bivariate comparison of medians of biomarker lev-
els and their ratios between groups was done using the
Mann–Whitney U test. Statistically significant difference
was considered if the p-value was below 0.05. All analyses
were generated using SPSS 20.0 (SPSS Inc., Chicago, IL,
USA).
Ethical consideration. The local Committee of Ethics ap-
proved study protocol before patient recruitment was
started. All patients signed an informed consent form prior
the admission.
RESULTS
The final sample included 673 patients: 141 patients in the
ERD group (median age 48 years (range 18–84), male/fe-
male ratio (M/F) — 68/83); 122 patients in the NERD
group (median age 45 years (range 18–78), M/F — 32/90)
and 410 patients in the control group (median age 50 years
(range 18–90), M/F — 97/313).
The distribution of ERD severity according to the Los An-
geles classification (Lundell et al., 1999) was as follows:
grade A — 108/141 (76.6%), grade B — 25/141 (17.7%),
grade C — 6/141 (4.3%), and grade D — 2/141 (1.4%).
Median level of G-17 was significantly lower in the ERD
group compared to control patients (respectively, 1.94
pmol/l versus 2.92 pmol/l, p = 0.036). Levels of all other
biomarkers and their ratio, with the exception of Pg1, sig-
nificantly differed between ERD group and control patients.
However, levels of biomarkers and their ratio did not sig-
nificantly differ between NERD and control group patients.
The bivariate comparison of levels of biomarkers and their
ratio is shown in the Table 2.
Patients who after histopathological evaluation showed po-
tential conditions that might modify levels of biomarkers
were excluded from the study groups: 81 patients from the
ERD group; 85 from the NERD group and 282 from the
control group (Table 3).
The numbers of remaining patients were 60 in the ERD
group, 37 in the NERD group and 128 in the control group.
After exclusion of the above patients, median level of G-17
in the ERD group showed no difference compared to con-
trol patients (respectively, 0.81 pmol/l versus 0.74 pmol/l,
p = 0.956). Levels of all other biomarkers and their ratios
were not significantly different in ERD and NERD groups
compared to control patients. The bivariate comparison of
levels of biomarkers after exclusion of all potential condi-
tions that might modify levels of biomarkers is shown in
Table 4.
DISCUSSION
Our study was focused on the evaluation of a possible alter-
native diagnostic method to distinguish GERD from other
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T a b l e 2














G-17 (pmol/l) 1.94 (0.54–5.72) 0.036 3.18 (0.80–9.53) 0.532 2.92 (0.57–10.11)
Pg1 (µg/l) 63.10 (50.91–92.04) 0.434 71.10 (51.26–96.55) 0.058 64.03 (44.05–89.85)
Pg2 (µg/l) 6.70 (4.84–10.80) 0.046 8.63 (5.05–12.82) 0.609 7.79 (5.24–13.03)
Pg1/Pg2 9.41 (7.02–11.95) 0.008 8.60 (6.40–11.82) 0.377 8.60 (5.23–11.30)
ERD, erosive reflux disease; NERD, non-erosive reflux disease; IQR, interquartile range; G-17, Gastrin-17; Pg1, Pepsinogen-1; Pg2, Pepsinogen-2
T a b l e 3
NUMBER OF IDENTIFIED POTENTIAL CONDITIONS THAT MIGHT








Antrum mucosa atrophy (any grade) 29 38 104
Corpus mucosa atrophy (any grade) 6 10 65
Helicobacter pylori colonization of
antrum mucosa
63 67 215
At least one from the above mentioned
factors present
81 85 282
ERD, erosive reflux disease; NERD, non-erosive reflux disease
patients with dyspepsia. Pathogenesis of GERD is linked to
the functional state of gastric mucosa, so it was thought that
measurement of biomarkers of gastric mucosa seemed to be
a promising diagnostic tool.
In our study prior exclusion of the patients having condi-
tions that may influence secretion of the biomarkers levels
of G-17 and Pg2 were significantly lower and Pg1/Pg2
higher in the ERD group compared to the control group.
However, after exclusion of all conditions (antrum and cor-
pus mucosa atrophy, Helicobacter pylori colonisation of an-
trum mucosa) that may influence levels of biomarkers, sig-
nificant differences were lost. A study by Malfertheiner’s
group on biomarker levels among various forms of GERD
showed similar results for a study population that had a
much lower rate of gastric mucosa atrophy and Helicobac-
ter pylori colonisation (Monkemuller et al., 2008).
No statistically significant difference among biomarker lev-
els was observed between NERD and the control group bef-
ore exclusion of all conditions that may influence biomarker
levels, nor after exclusion of those conditions. However, in
a study from Japan, NERD was linked with decreased level
of Pg1/Pg2 (Fujiwara et al., 2005). Another study from Ja-
pan found that both ERD and NERD patients had increased
level of Pg1/Pg2 (Minatsuki et al., 2013).
In our study almost all patients in the ERD group presented
in the A or B esophagitis stage, which may have influenced
the obtained results. However, a significant difference was
also not observed in the levels of biomarkers in a matched
case-control study (Monkemuller et al., 2008).
Although BE is considered as a form of GERD, the sampled
group in our study contained no BE patients. A lower level
of G-17 (Sipponen et al., 2005) and higher level of Pg1
(Abe et al., 2009) have been observed in BE patients.
On the one hand, levels of biomarkers are indirect indica-
tors of the functional state of gastric mucosa, which is why
they can be successfully used for non-invasive diagnostic of
atrophic gastritis (Kuipers, 2003; Vaananen et al., 2003;
Pasechnikov et al., 2005; Iijima et al., 2009; Narsol-
lahzadeh et al., 2011). On the other hand, this likely is not
be the case for GERD patients (Peitz et al., 2011). Our data
support the idea that GERD is a complex disease and it has
a very complex pathophysiology; probably, increased gas-
tric acid secretion is not the most important pathophysio-
logical mechanism in ERD and NERD.
The most important limitation of our study was that the con-
trol group was represented not by healthy individuals, but
by patients with various complaints from the side of upper
gastrointestinal system. It is known that the pattern of pep-
sinogen secretion varies among patients with functional
dyspepsia (Yoshikawa et al., 2002).
In summary, Pg1, Pg2, and G-17 based tests cannot be used
to distinguish ERD or NERD from other dyspeptic patients.
Also, ERD and NERD patients cannot be distinguished us-
ing serological tests only.
Considering the gastric acid secretion profile differs in BE
compared to other patients, future studies should focus on
clarifying the role of pepsinogen-based tests in the screen-
ing and diagnosis of BE.
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GASTROEZOFAGEÂLÂ ATVIÏÒA NEINVAZÎVA DIAGNOSTIKA, IZMANTOJOT GASTRÎNA UN PEPSÎNA TESTUS
Gastrîns-17 (G-17), pepsinogçns-1 (Pg1) un pepsinogçns-2 (Pg2) atspoguïo kuòìa gïotâdas funkcionâlo stâvokli, un tos izmanto atrofiska
gastrîta neinvazîvai diagnostikai un skrîningam. Pçtîjuma mçríis bija izvçrtçt, vai ir iespçjams atðíirt erozîva gastroezofageâlâ atviïòa
(EGEA) un ne-EGEA (NEGEA) pacientus no pârçjiem pacientiem ar dispepsiju, izmantojot specifiskus neinvazîvus maríierus. G-17, Pg1
un Pg2 koncentrâcijas asinîs tika izmçrîtas 141 EGEA pacientiem (vecuma mediâna 48 gadi, vîrieði – 68), 122 NEGEA pacientiem
(vecuma mediâna 45 gadi, vîrieði – 32) un 410 kontroles pacientiem (vecuma mediâna 50 gadi, vîrieði – 97). Biomaríieru koncentrâcijas
EGEA un NEGEA pacientiem tika salîdzinâtas ar kontroles grupu. EGEA pacientiem G-17 (1,94 vs 2,92 pmol/L, p = 0,036) un Pg2 (6,70
vs 7,79 µg/L, p = 0,046) koncentrâcijas bija zemâkas, salîdzinot ar kontroles pacientiem, savukârt, NEGEA grupas biomaríieru
koncentrâcijas bûtiski neatðíîrâs. Pçc to pacientu izslçgðanas no analîzes, kuriem bija vismaz viens faktors, kas var ietekmçt biomaríieru
koncentrâciju asinîs (kuòìa gïotâdas atrofija, Helicobacter pylori kolonizâcija), nozîmîgas biomaríieru koncentrâcijas atðíirîbas netika
novçrotas. Testus G-17, Pg1 un Pg2 koncentrâciju noteikðanai nevar izmantot EGEA un NEGEA atklâðanai dispeptisko pacientu vidû.
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